SEC Filings

10-K
AVEXIS, INC. filed this Form 10-K on 03/18/2016
Entire Document
 

Table of Contents

        The following table sets forth the aggregate number of shares of Class D preferred stock issued to our related parties in this preferred stock financing:

PARTICIPANTS
  SHARES OF
CLASS D
PREFERRED
STOCK
 

Stockholders affiliated with T. Rowe Price

    951,720  

Deerfield(1)

    117,996  

Deerfield Special Situations Fund, L.P.(1). 

    117,998  

Roche

    163,139  

Venrock(2)

    223,880  

VHCP Co-Investment Holdings II, LLC.(2)

    90,779  

(1)
Deerfield Special Situations Fund, L.P. is associated with Deerfield.

(2)
VHCP Co-Investment Holdings II, LLC is associated with Venrock.

Investor Rights Agreement

        In connection with our Class B preferred stock financing in March 2014 we entered into an investor rights agreement, which was (i) amended and restated in connection with our Class C preferred stock financing in August 2014, (ii) further amended and restated in April 2015 and (iii) amended and restated in connection with our Class D preferred stock financing in September 2015 and (iv) further amended effective as of October 2015. The third amended and restated investor rights agreement, as amended, contained voting rights, information rights, rights of co-sale, pro rata participation rights and registration rights, among other things, with certain holders of our capital stock. In addition, as described in "Board Composition" in Item 10 of this Annual Report, prior to the closing of our initial public offering in February 2016, the third amended and restated investor rights agreement, as amended, entitled certain holders of our capital stock to designate directors to our board. Pursuant to the terms of the agreement, each of these rights, with the exception of the registrations rights, terminated upon the closing of the initial public offering, except for the registration rights.

REGENXBIO Exclusive License Agreement

        In March 2014, we entered into an exclusive license agreement with ReGenX Biosciences, LLC, or ReGenX, predecessor to REGENXBIO Inc, as described more fully in "Business—Our Collaboration and License Agreements—Strategic Collaborators and Relationships—REGENXBIO" in Item 1 of this Annual Report. Venrock, a former beneficial owner of more than 5% of our capital stock, is a beneficial owner of more than 5% of the capital stock of REGENXBIO, as of December 31, 2015, and Deerfield, a beneficial owner of more than 5% of our capital stock, is a former beneficial owner of 5% of the capital stock of REGENXBIO. Our payments to ReGenX totaled $2.3 million through December 31, 2015, which includes $0.3 million in aggregate milestone payments.

Employment Agreements

        We have entered into employment-related agreements with our current and former executive officers, including Mr. Carbona. For more information regarding these agreements, see "Executive Compensation—Employment Agreements" and "Executive Compensation—Potential Payments Upon Termination or Change in Control" in Item 11 of this Annual Report.

Employment of Dr. Allan Kaspar

        Since July 2013, Sixeva, Inc., our wholly-owned subsidiary, and beginning in January 2014, we have employed Dr. Allan Kaspar, the brother of Dr. Brian Kaspar. Dr. Allan Kaspar is currently our Vice President, Research and Development. In 2014 and 2015, his compensation was $181,692 and $193,932,

196



© AveXis, Inc. All Rights Reserved.